Last reviewed · How we verify

NCT01682837

Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension

Completed Phase 2 Results posted Last updated 17 March 2017
What this trial tests

Phase 2 trial testing Potassium chloride powder in Hypertension in 35 participants. Completed in 1 March 2015.

Timeline
1 October 2012
Primary endpoint
1 March 2015
1 March 2015

Quick facts

Lead sponsorUniversity of Texas Southwestern Medical Center
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingquadruple
Primary purposetreatment
Enrollment35
Start date1 October 2012
Primary completion1 March 2015
Estimated completion1 March 2015
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Texas Southwestern Medical Center

Who can join

21 and older, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

Liquid potassium-magnesium citrate (KMgCit) as a pharmaceutical formulation will lower blood pressure among patients with pre- or Stage I hypertension on their customary diet.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hypertension

Currently open trials in the same condition.

Other University of Texas Southwestern Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01682837.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing